Regeneron plans $1B stock buyback; Merck partner touts PhIIb results for Keytruda combo in pancreatic cancer
→ With a solid third quarter, driven by sales of Dupixent, and flush with more than $6 billion in cash — Regeneron $REGN on Tuesday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
